Monograph Details
|
|
Dermatological Disorders
> Psoriasis
|
|
HUMIRA |
| Manufacturer |
|
Abbott Laboratories |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Tumor necrosis factor-α blocker. |
| Generic Name |
|
Adalimumab 20mg/0.4mL, 40mg/0.8mL; soln for SC inj; preservative-free. |
| Indications |
|
Moderate-to-severe chronic plaque psoriasis in adults who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. |
| Children |
|
<18yrs: not recommended. |
| Adults |
|
Inject SC into thigh or abdomen; rotate inj sites; supervise 1st dose. ≥18yrs: initially 80mg, followed by 40mg every other week starting one week after initial dose. |
| Contraindications |
|
Concurrent anakinra: not recommended. Sepsis. Clinically important, active infection. Concurrent live vaccines or other TNF blockers. |
| Precautions |
|
Chronic or history of recurring infections. Conditions that predispose to infection. Test for tuberculosis; treat TB first. Monitor closely if new infection develops; discontinue if serious infection or sepsis develops. CHF. Immunosuppression. Discontinue if lupus-like syndrome with antibody formation or serious hypersensitivity reaction occurs. CNS demyelinating disorders. Juvenile arthritis: follow up on current immunizations before starting therapy. Latex allergy. Elderly. Pregnancy (Cat.B). Nursing mothers: not recommended. |
| Adverse Reactions |
|
Inj site reactions, infections (may be serious), headache, nausea, rash, abdominal pain; rare: malignancies (eg, lymphoma), blood dyscrasias, hypertension, neurological events, antibody formation, lupus-like syndrome. |
| How Supplied |
Single-dose prefilled syringe—2
Single-dose prefilled pen (40mg)—2 |
|
|
|
|
